Pharsight

1. Amzeeq patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945516	JOURNEY	Surfactant-free water-free foamable compositions, breakable foams and gels and their uses	Oct, 2030 (6 years from now)
US9675700	JOURNEY	Topical tetracycline compositions	Oct, 2030 (6 years from now)
US10517882	JOURNEY	Method for healing of an infected acne lesion without scarring	Oct, 2030 (6 years from now)
US10821187	JOURNEY	Compositions, gels and foams with rheology modulators and uses thereof	Oct, 2030 (6 years from now)
US10213512	JOURNEY	Topical tetracycline compositions	Oct, 2030 (6 years from now)
US10265404	JOURNEY	Compositions, gels and foams with rheology modulators and uses thereof	Oct, 2030 (6 years from now)
US8992896	JOURNEY	Topical tetracycline compositions	Oct, 2030 (6 years from now)
US10137200	JOURNEY	Surfactant-free water-free foamable compositions, breakable foams and gels and their uses	Oct, 2030 (6 years from now)
US8865139	JOURNEY	Topical tetracycline compositions	Oct, 2030 (6 years from now)
US10086080	JOURNEY	Topical tetracycline compositions	Oct, 2030 (6 years from now)
US10398641	JOURNEY	Compositions and methods for treating rosacea and acne	Sep, 2037 (13 years from now)
US10849847	JOURNEY	Compositions and methods for treating rosacea and acne	Sep, 2037 (13 years from now)

Market Authorisation Date: 18 October, 2019

Treatment: Treatment of non-nodular acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.04	11 May, 2021	1		08 Sep, 2037

Strength	Dosage	Availability
EQ 4% BASE	AEROSOL, FOAM;TOPICAL	Prescription

AMZEEQ family patents

2. Arestin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6682348	ORAPHARMA	Dispensing apparatus and cartridge	Mar, 2022 (2 years ago)
US7699609	ORAPHARMA	Dispensing apparatus and cartridge with deformable tip	Mar, 2022 (2 years ago)

Market Authorisation Date: 16 February, 2001

Treatment: NA

Dosage: POWDER, EXTENDED RELEASE;DENTAL

Strength	Dosage	Availability
EQ 1MG BASE	POWDER, EXTENDED RELEASE;DENTAL	Prescription

ARESTIN family patents

3. Minocin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9084802	REMPEX	Tetracycline compositions	May, 2031 (7 years from now)
US9278105	REMPEX	Tetracycline compositions	May, 2031 (7 years from now)

Treatment: Method of treating bacterial infections

Dosage: INJECTABLE;INJECTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg/vial	16 Oct, 2020	1	22 Jul, 2022	12 May, 2031	Eligible

Strength	Dosage	Availability
EQ 100MG BASE/VIAL	INJECTABLE;INJECTION	Prescription

MINOCIN family patents

4. Minolira patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103517	EPI HLTH	Pharmaceutical compositions for minocycline	Apr, 2036 (11 years from now)

Market Authorisation Date: 08 May, 2017

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 135MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 105MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

MINOLIRA family patents

5. Solodyn patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5908838	BAUSCH	Method for the treatment of acne	Feb, 2018 (6 years ago)
US8268804	BAUSCH	Minocycline oral dosage forms for the treatment of acne	Jun, 2025 (1 year, 1 month from now)
US8722650	BAUSCH	Extended-release minocycline dosage forms	Jun, 2025 (1 year, 1 month from now)
US7790705	BAUSCH	Minocycline oral dosage forms for the treatment of acne	Jun, 2025 (1 year, 1 month from now)
US8252776	BAUSCH	Minocycline oral dosage forms for the treatment of acne	Jun, 2025 (1 year, 1 month from now)
US7919483	BAUSCH	Method for the treatment of acne	Mar, 2027 (2 years from now)
US7541347	BAUSCH	Minocycline oral dosage forms for the treatment of acne	Apr, 2027 (2 years from now)
US7544373	BAUSCH	Minocycline oral dosage forms for the treatment of acne	Apr, 2027 (2 years from now)
US9192615	BAUSCH	Method for the treatment of acne and certain dosage forms thereof	Nov, 2031 (7 years from now)

Market Authorisation Date: 08 May, 2006

Treatment: Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris; Treatment of acne

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
45 mg, 90 mg and 135 mg
55 mg	02 Dec, 2010	1	30 Nov, 2011	20 Nov, 2025	Eligible
65 mg and 115 mg	19 Nov, 2009	1	18 May, 2012	19 Feb, 2018	Extinguished Eligible
80 mg	27 Oct, 2010	1	25 Sep, 2014	19 Feb, 2018	Non-Forfeiture
105 mg	13 Dec, 2010	1		19 Feb, 2018	Non-Forfeiture

Strength	Dosage	Availability
EQ 105MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 115MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 45MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued
EQ 55MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 135MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued
EQ 90MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued
EQ 80MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 65MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

SOLODYN family patents

6. Ximino patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5908838	JOURNEY	Method for the treatment of acne	Feb, 2018 (6 years ago)
US7790705	JOURNEY	Minocycline oral dosage forms for the treatment of acne	Jun, 2025 (1 year, 1 month from now)
US8268804	JOURNEY	Minocycline oral dosage forms for the treatment of acne	Jun, 2025 (1 year, 1 month from now)
US8252776	JOURNEY	Minocycline oral dosage forms for the treatment of acne	Jun, 2025 (1 year, 1 month from now)
US7919483	JOURNEY	Method for the treatment of acne	Mar, 2027 (2 years from now)
US7544373	JOURNEY	Minocycline oral dosage forms for the treatment of acne	Apr, 2027 (2 years from now)
US7541347	JOURNEY	Minocycline oral dosage forms for the treatment of acne	Apr, 2027 (2 years from now)

Market Authorisation Date: 11 July, 2012

Treatment: Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris; Treatment of acne

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 45MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
EQ 135MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
EQ 90MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued

XIMINO family patents

7. Zilxi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10946101	JOURNEY	Surfactant-free water-free foamable compositions, breakable foams and gels and their uses	Oct, 2030 (6 years from now)
US10322186	JOURNEY	Topical tetracycline compositions	Oct, 2030 (6 years from now)
US10213512	JOURNEY	Topical tetracycline compositions	Oct, 2030 (6 years from now)
US9675700	JOURNEY	Topical tetracycline compositions	Oct, 2030 (6 years from now)
US8992896	JOURNEY	Topical tetracycline compositions	Oct, 2030 (6 years from now)
US8865139	JOURNEY	Topical tetracycline compositions	Oct, 2030 (6 years from now)
US10265404	JOURNEY	Compositions, gels and foams with rheology modulators and uses thereof	Oct, 2030 (6 years from now)
US8945516	JOURNEY	Surfactant-free water-free foamable compositions, breakable foams and gels and their uses	Oct, 2030 (6 years from now)

Market Authorisation Date: 28 May, 2020

Treatment: Treatment of inflammatory lesions of rosacea.